Literature DB >> 2188129

Activation of coagulation after administration of tumor necrosis factor to normal subjects.

T van der Poll1, H R Büller, H ten Cate, C H Wortel, K A Bauer, S J van Deventer, C E Hack, H P Sauerwein, R D Rosenberg, J W ten Cate.   

Abstract

Tumor necrosis factor has been implicated in the activation of blood coagulation in septicemia, a condition commonly associated with intravascular coagulation and disturbances of hemostasis. To evaluate the early dynamics and the route of the in vivo coagulative response to tumor necrosis factor, we performed a controlled study in six healthy men, monitoring the activation of the common and intrinsic pathways of coagulation with highly sensitive and specific radioimmunoassays. Recombinant human tumor necrosis factor, administered as an intravenous bolus injection (50 micrograms per square meter of body-surface area), induced an early and short-lived rise in circulating levels of the activation peptide of factor X, reaching maximal values after 30 to 45 minutes (mean +/- SEM increase after 45 minutes, 34.2 +/- 18.2 percent; tumor necrosis factor vs. saline, P = 0.015). This was followed by a gradual and prolonged increase in the plasma concentration of the prothrombin fragment F1+2, peaking after four to five hours (mean increase after five hours, 348.0 +/- 144.8 percent; tumor necrosis factor vs. saline, P less than 0.0001). These findings signify the formation of factor Xa (activated factor X) and the activation of prothrombin. Activation of the intrinsic pathway could not be detected by a series of measurements of the plasma levels of factor XII, prekallikrein, factor XIIa-C1 inhibitor complexes, kallikrein-C1 inhibitor complexes, and the activation peptide of factor IX. The delay between the maximal activation of factor X and that of prothrombin amounted to several hours, indicating that neutralization of factor Xa activity was slow. We conclude that a single injection of tumor necrosis factor elicits a rapid and sustained activation of the common pathway of coagulation, probably induced through the extrinsic route. Our results suggest that tumor necrosis factor could play an important part in the early activation of the hemostatic mechanism in septicemia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2188129     DOI: 10.1056/NEJM199006073222302

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  103 in total

Review 1.  Tissue factor and thrombosis: The clot starts here.

Authors:  A Phillip Owens; Nigel Mackman
Journal:  Thromb Haemost       Date:  2010-06-10       Impact factor: 5.249

2.  Adjunctive Therapies for Sepsis and Septic Shock.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

Review 3.  Disseminated intravascular coagulation: old disease, new hope.

Authors:  Cheng Hock Toh; Michael Dennis
Journal:  BMJ       Date:  2003-10-25

Review 4.  Emerging therapies in severe sepsis.

Authors:  S J Finney; T W Evans
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

5.  p21-activated kinase-1 signaling regulates transcription of tissue factor and tissue factor pathway inhibitor.

Authors:  Beatriz Sánchez-Solana; Mona Motwani; Da-Qiang Li; Jeyanthy Eswaran; Rakesh Kumar
Journal:  J Biol Chem       Date:  2012-10-04       Impact factor: 5.157

6.  Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.

Authors:  B Eisele; M Lamy; L G Thijs; H O Keinecke; H P Schuster; F R Matthias; F Fourrier; H Heinrichs; U Delvos
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

Review 7.  Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analogues.

Authors:  Aileen F B White; Alexei V Demchenko
Journal:  Adv Carbohydr Chem Biochem       Date:  2014       Impact factor: 12.200

Review 8.  Pathogenesis of malaria and clinically similar conditions.

Authors:  Ian A Clark; Lisa M Alleva; Alison C Mills; William B Cowden
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

Review 9.  Venous thrombosis and prothrombotic factors in inflammatory bowel disease.

Authors:  Fernando Magro; João-Bruno Soares; Dália Fernandes
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

10.  In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.

Authors:  K J Parlevliet; I J ten Berge; S L Yong; J Surachno; J M Wilmink; P T Schellekens
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.